PhenoAge vs chronological age and KDM-BA for mortality prediction in COPD
In 19,882 patients with COPD from a biobank cohort, PhenoAge predicted all-cause mortality better than chronological age and KDM-BA at 5, 10 and 15 years; PhenoAge-based models improved risk prediction modestly but consistently. [1]
Automatic summary · not editorially reviewed
The key findings
The study included 19,882 patients with COPD recruited between 2006 and 2010 from a large biobank cohort, with survival data beyond 10 years. [1]
PhenoAge consistently outperformed chronological age, PhenoAge acceleration and KDM-BA in predicting all-cause mortality at 5-, 10- and 15-year follow-up. [1]
PhenoAge-based models provided modest but consistent improvements in risk prediction over chronological-age models and may complement individualized risk stratification. [1]
The source at a glance
- Study type / format
- Cohort study using biobank data with mortality prediction modelling (abstract).
- Population / context
- 19,882 patients with COPD from a large biobank cohort, recruited 2006–2010.
- Summary based on
- Study abstract
- Original publication
- August 19, 2026
COPD biobank cohort compared two biological age measures
The study asked how well biological age predicts death in COPD and which biomarker works best. It included 19,882 patients with COPD and survival data beyond 10 years, recruited 2006–2010 from a large biobank cohort. Biological aging was measured with phenotypic age (PhenoAge) and the Klemera-Doubal Method biological age (KDM-BA). Mean chronological age was 59.9 years, mean PhenoAge 53.4 years and mean KDM-BA 58.9 years.
Supporting source [1]
PhenoAge predicted mortality better at 5, 10 and 15 years
Time-dependent ROC analyses compared how well the biomarkers distinguished patients who died from those who did not. PhenoAge consistently outperformed chronological age, PhenoAge acceleration and KDM-BA in predicting all-cause mortality at 5-, 10- and 15-year follow-up. Two Cox models were built; models with PhenoAge had higher AUCs and positive net reclassification index and integrated discrimination improvement values than chronological-age models. Decision curve analysis indicated greater net clinical benefit for PhenoAge models across most threshold probabilities.
Supporting source [1]
Modest, consistent gains; abstract-only scope limits interpretation
The authors conclude that PhenoAge-based models gave modest but consistent improvements over chronological-age models and may complement individualized risk stratification. This is a prediction study, not evidence that biological age causes death or that changing it extends life. Only the abstract was reviewed; the full text was not reviewed, so details of model variables, calibration and follow-up handling are not assessed here.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. Model variables, calibration and follow-up handling are not assessed. Predictive associations do not show that biological age causes mortality.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Cheng W, Hou Y, Zhou A, Liu C, Huang S, Zhao Y, Li J, Deng Z, Zhang T, Mao R, Tang Y, Pan P. · europepmc.org · August 19, 2026